Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Discussion Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19.

http://nn.neurology.org/cgi/content/short/9/6/e200021?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - August 29, 2022 Category: Neurology Authors: Simpson-Yap, S., Pirmani, A., Kalincik, T., De Brouwer, E., Geys, L., Parciak, T., Helme, A., Rijke, N., Hillert, J. A., Moreau, Y., Edan, G., Sharmin, S., Spelman, T., McBurney, R., Schmidt, H., Bergmann, A. B., Braune, S., Stahmann, A., Middleton, R. M. Tags: COVID-19, Multiple sclerosis, All epidemiology, Risk factors in epidemiology Research Article Source Type: research